Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC(50)s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.
Depatureaux
Agnès
A
Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France.
Charpentier
Charlotte
C
Collin
Gilles
G
Leoz
Marie
M
Descamps
Diane
D
Vessière
Aurélia
A
Damond
Florence
F
Rousset
Dominique
D
Brun-Vézinet
Françoise
F
Plantier
Jean-Christophe
JC
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000077560:Enfuvirtide; D005838:Genotype; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics* / Q000472:pathogenicity; D006801:Humans; D020128:Inhibitory Concentration 50; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000627:therapeutic use*; D010641:Phenotype
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide